Correlation Between Mink Therapeutics and Rigel Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mink Therapeutics and Rigel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mink Therapeutics and Rigel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mink Therapeutics and Rigel Pharmaceuticals, you can compare the effects of market volatilities on Mink Therapeutics and Rigel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mink Therapeutics with a short position of Rigel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mink Therapeutics and Rigel Pharmaceuticals.

Diversification Opportunities for Mink Therapeutics and Rigel Pharmaceuticals

-0.22
  Correlation Coefficient

Very good diversification

The 3 months correlation between Mink and Rigel is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Mink Therapeutics and Rigel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rigel Pharmaceuticals and Mink Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mink Therapeutics are associated (or correlated) with Rigel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rigel Pharmaceuticals has no effect on the direction of Mink Therapeutics i.e., Mink Therapeutics and Rigel Pharmaceuticals go up and down completely randomly.

Pair Corralation between Mink Therapeutics and Rigel Pharmaceuticals

Given the investment horizon of 90 days Mink Therapeutics is expected to under-perform the Rigel Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Mink Therapeutics is 3.98 times less risky than Rigel Pharmaceuticals. The stock trades about -0.01 of its potential returns per unit of risk. The Rigel Pharmaceuticals is currently generating about 0.34 of returns per unit of risk over similar time horizon. If you would invest  1,434  in Rigel Pharmaceuticals on August 30, 2024 and sell it today you would earn a total of  1,354  from holding Rigel Pharmaceuticals or generate 94.42% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Mink Therapeutics  vs.  Rigel Pharmaceuticals

 Performance 
       Timeline  
Mink Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mink Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's forward-looking signals remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Rigel Pharmaceuticals 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Rigel Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Rigel Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.

Mink Therapeutics and Rigel Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mink Therapeutics and Rigel Pharmaceuticals

The main advantage of trading using opposite Mink Therapeutics and Rigel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mink Therapeutics position performs unexpectedly, Rigel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rigel Pharmaceuticals will offset losses from the drop in Rigel Pharmaceuticals' long position.
The idea behind Mink Therapeutics and Rigel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance